News

This month in review features 7 allergy headlines in February 2026: FDA's decision on Dupilumab for AFRS, late-breaking data presented at AAAAI, & more.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline results from the TRIUMPH-4 trial, demonstrating retatrutide's efficacy in promoting weight loss.

Twice-daily delgocitinib cream 20 mg/g in those with moderate to severe chronic hand eczema led to significant HRQoL improvements.

Shamji discussed the advantages of PQ grass over conventional immunotherapy at AAAAI 2026.

A randomized crossover study shows that most patients prefer intranasal epinephrine for anaphylaxis due to its ease of use, portability, and the absence of needles.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recently published trial results and what they mean for Eli Lilly’s newest GLP-1 molecule.

New research suggests MASLD risk may develop early in life, highlighting the impact of parental factors and cumulative childhood adiposity.

In the final part of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

In part 5 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

In part 3 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

In part 2 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

In part 1 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

COMBINE trial data show dupilumab added to omalizumab-assisted OIT improved desensitization and reduced GI symptoms, despite no sustained response benefit.

FDA-approved iptacopan and pegcetacoplan offer new complement-targeted therapies for C3 glomerulopathy.

This segment of the latest episode of The Medical Sisterhood podcast highlights the value of a supportive partner among those who are physician parents.

Hosts are joined by Su Wang, MD, MPH, to discuss the evolving management of hepatitis B and how to move care beyond silos with expanded treatment and provider empowerment.

Han discusses late-breaking phase 2 VIBRANT data at AAAAI 2026, which showed that quarterly TSLP receptor blockade reduced the need for CRSwNP by 76%.

The nephrology field continued to see advances in February 2026, with 5 headlines clincians may have missed.

Gu explains how addiction drives GI and liver disease and why integrated care is key to improving outcomes and survival.

Barzolvolimab therapy resulted in significant improvement of cold urticaria (ColdU) following 20 weeks of treatment.

Pooled REMIX-1/-2 data show remibrutinib reduced CSU activity within 12 hours, with greater UAS improvements vs placebo through day 7.

This World Obesity Day, catch up on major paradigm shifts in the diagnosis, discussion, and treatment of obesity, one of the world’s most devastating chronic diseases.

In this February review of the most significant developments in dermatology, the month’s most notable coverage of disease states such as psoriasis and atopic dermatitis is highlighted.

Cogent Biosciences previously submitted an NDA for bezuclastinib at the end of 2025.

Nadkarni’s research suggests LLMs often pass along medical misinformation, underscoring the need for oversight, evaluation, and stronger AI guardrails.

In this segment of the recent Skin of Color Savvy podcast, the value of advocacy and meaningful change in skin health equity is highlighted.

Catch up with FDA decisions, key trial results, podcast updates, and more.

Lyskjaer walks clinicians through 10-year data from a nationwide cohort study comparing ablation and surgery for renal cancer.